Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

ABSTRACT: INTRODUCTION: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to retrospectively explore the prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Cuesta, Lynnette, Oakman, Catherine, Falagan-Lotsch, Priscila, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia, Larsimont, Denis, Francis, Prudence A, Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446332/
https://www.ncbi.nlm.nih.gov/pubmed/22551440
http://dx.doi.org/10.1186/bcr3179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446332/
https://www.ncbi.nlm.nih.gov/pubmed/22551440
http://dx.doi.org/10.1186/bcr3179

Ejemplares similares